文献速递造血干细胞移植与细胞治疗白血病

中间强度双份脐血移植在成人中实现高无进展生存率

High progression-free survival after intermediate intensity double unit cord blood transplantation in adults.
PubMed 文献 · Blood Adv · 2020-01-01

3年总生存率82%,无进展生存率76%,移植相关死亡率15%,复发率9%,证实中间强度双份脐血移植可获得高无进展生存率。

要点

  • 中间强度双份脐血移植3年无进展生存率达76%,总生存率82%
  • 移植相关死亡率和复发率分别为15%和9%,复发率低
  • 年轻年龄和植入单位高CD34+细胞剂量改善移植相关死亡率和总生存率

核心结论

  • 中间强度双份脐血移植与高无进展生存率相关。
  • 使用高度HLA不合且未处理的移植物允许该疗法的广泛应用。
  • 低复发率支持即使在MRD阳性患者中也存在强效移植物抗白血病效应。

研究设计与样本

  • 患者接受基于环孢素A/霉酚酸酯的中间强度预处理方案:环磷酰胺50 mg/kg、氟达拉滨150 mg/m2、噻替哌10 mg/kg、全身照射400 cGy,并进行未处理双份脐血移植。
  • 移植物选择优先考虑脐血单位质量和CD34+细胞剂量,中位每单位CD34+细胞剂量1.3×10^5/kg(范围0.2-8.3),中位供受者HLA匹配5/8(范围3-7/8)。

主要发现

  • 持续脐血植入、第180天III-IV级急性移植物抗宿主病和3年慢性移植物抗宿主病的累积发生率分别为99%、24%和7%。
  • 3年移植相关死亡率和复发率分别为15%和9%。
  • 3年总生存率为82%,无进展生存率为76%。
  • 年轻年龄和植入单位较高CD34+细胞剂量均改善移植相关死亡率和总生存率,但均不影响无进展生存率。
  • 植入单位-受者HLA匹配与任何结局均无关,39例植入3-4/8 HLA匹配单位的患者3年无进展生存率为79%。

临床怎么用

  • 中间强度双份脐血移植可作为成人血液病患者的治疗选择,尤其适用于需要广泛可及性移植物的情况。
  • 移植物选择时应优先考虑脐血单位质量和CD34+细胞剂量。
  • 高度HLA不合的未处理脐血单位可使用,且不影响移植结局。
  • 对于MRD阳性患者,该方案仍可获得较好的无进展生存率,提示强效移植物抗白血病效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cord blood transplantation (CBT) after high intensity or nonmyeloablative conditioning has limitations. We investigated cyclosporine-A/mycophenolate mofetil-based intermediate intensity (cyclophosphamide 50 mg/kg, fludarabine 150 mg/m2, thiotepa 10 mg/kg, total body irradiation 400 cGy) unmanipulated double-unit CBT (dCBT) with prioritization of unit quality and CD34+ cell dose in graft selection. Ninety adults (median age, 47 years [range, 21-63]; median hematopoietic cell transplantation comorbidity index, 2 [range, 0-8]; 61 [68%] acute leukemia) received double-unit grafts (median CD34+ cell dose, 1.3 × 105/kg per unit [range, 0.2-8.3]; median donor-recipient human leukocyte antigen (HLA) match, 5/8 [range 3-7/8]). The cumulative incidences of sustained CB engraftment, day 180 grade III-IV acute, and 3-year chronic graft-versus-host disease were 99%, 24%, and 7%, respectively. Three-year transplant-related mortality (TRM) and relapse incidences were 15% and 9%, respectively. Three-year overall survival (OS) is 82%, and progression-free survival (PFS) is 76%. Younger age and higher engrafting unit CD34+ cell dose both improved TRM and OS, although neither impacted PFS. Engrafting unit-recipient HLA match was not associated with any outcome with a 3-year PFS of 79% in 39 patients engrafting with 3-4/8 HLA-matched units. In 52 remission acute leukemia patients, there was no association between minimal residual disease (MRD) and 3-year PFS: MRD negative of 88% vs MRD positive of 77% (P = .375). Intermediate intensity dCBT is associated with high PFS. Use of highly HLA mismatched and unmanipulated grafts permits wide application of this therapy, and the low relapse rates support robust graft-versus-leukemia effects even in patients with MRD.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Barker JN, Devlin SM, Naputo KA, et al. High progression-free survival after intermediate intensity double unit cord blood transplantation in adults. Blood Adv. 2020. PMID: 33290545. doi:10.1182/bloodadvances.2020003371

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。